
Metropolis (METROPOLIS) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
3.9B
Gross Profit
3.0B
78.05%
Operating Income
589.1M
15.26%
Net Income
452.5M
11.72%
EPS (Diluted)
₹8.66
Balance Sheet Metrics
Total Assets
18.7B
Total Liabilities
5.3B
Shareholders Equity
13.3B
Debt to Equity
0.40
Cash Flow Metrics
Operating Cash Flow
491.2M
Free Cash Flow
320.7M
Revenue & Profitability Trend
Metropolis Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 13.3B | 12.1B | 11.5B | 12.3B | 10.0B |
Cost of Goods Sold | 2.8B | 2.6B | 2.6B | 2.9B | 2.6B |
Gross Profit | 10.5B | 9.5B | 8.8B | 9.4B | 7.4B |
Gross Margin % | 78.7% | 78.4% | 77.0% | 76.6% | 73.9% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 1.9B | 1.7B | 1.6B | 1.7B | 971.5M |
Other Operating Expenses | 1.0B | 1.0B | 802.7M | 753.3M | 859.6M |
Total Operating Expenses | 2.9B | 2.7B | 2.4B | 2.5B | 1.8B |
Operating Income | 2.1B | 2.0B | 2.1B | 2.9B | 2.5B |
Operating Margin % | 15.5% | 16.8% | 18.2% | 23.5% | 24.7% |
Non-Operating Items | |||||
Interest Income | 35.1M | 32.6M | 57.1M | 111.5M | 93.0M |
Interest Expense | 185.7M | 225.4M | 268.0M | 197.4M | 77.8M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 1.9B | 1.7B | 1.9B | 2.9B | 2.4B |
Income Tax | 453.4M | 462.3M | 441.1M | 786.6M | 609.7M |
Effective Tax Rate % | 23.8% | 26.5% | 23.5% | 26.8% | 25.0% |
Net Income | 1.5B | 1.3B | 1.4B | 2.1B | 1.8B |
Net Margin % | 10.9% | 10.6% | 12.5% | 17.5% | 18.4% |
Key Metrics | |||||
EBITDA | 3.1B | 2.9B | 3.0B | 3.6B | 3.0B |
EPS (Basic) | ₹28.29 | ₹24.95 | ₹27.91 | ₹41.87 | ₹35.97 |
EPS (Diluted) | ₹28.15 | ₹24.87 | ₹27.81 | ₹41.66 | ₹35.79 |
Basic Shares Outstanding | 51252650 | 51219781 | 51196399 | 51156132 | 50903685 |
Diluted Shares Outstanding | 51252650 | 51219781 | 51196399 | 51156132 | 50903685 |
Income Statement Trend
Metropolis Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 394.8M | 626.2M | 688.3M | 659.8M | 3.9B |
Short-term Investments | 787.8M | 616.7M | 252.4M | 1.1B | 338.4M |
Accounts Receivable | 1.5B | 1.3B | 1.2B | 1.4B | 1.2B |
Inventory | 478.4M | 386.9M | 445.9M | 511.1M | 405.5M |
Other Current Assets | 246.1M | 202.8M | 159.4M | 143.1M | -4.6M |
Total Current Assets | 3.5B | 3.2B | 3.0B | 3.9B | 6.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 2.8B | 2.6B | 2.5B | 1.9B | 1.7B |
Goodwill | 16.8B | 13.0B | 12.8B | 12.7B | 2.2B |
Intangible Assets | 5.0B | 3.9B | 3.7B | 3.6B | 345.9M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | -12.0K | -1.0K | -347 | -2.0K | 6.7M |
Total Non-Current Assets | 15.2B | 12.4B | 12.0B | 11.4B | 4.0B |
Total Assets | 18.7B | 15.6B | 15.0B | 15.3B | 10.0B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 1.3B | 994.4M | 940.8M | 1.0B | 1.1B |
Short-term Debt | 920.7M | 780.0M | 1.1B | 1.4B | 333.4M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 1.0K | 240.1M | -1.0K | 53.5M | 146.2M |
Total Current Liabilities | 2.9B | 2.5B | 2.6B | 3.0B | 2.0B |
Non-Current Liabilities | |||||
Long-term Debt | 1.1B | 1.2B | 1.5B | 2.4B | 789.3M |
Deferred Tax Liabilities | 995.1M | 750.5M | 782.4M | 866.7M | 41.6M |
Other Non-Current Liabilities | - | - | 1.0K | - | - |
Total Non-Current Liabilities | 2.4B | 2.1B | 2.5B | 3.4B | 923.9M |
Total Liabilities | 5.3B | 4.6B | 5.1B | 6.4B | 3.0B |
Equity | |||||
Common Stock | 103.6M | 102.5M | 102.4M | 102.3M | 102.2M |
Retained Earnings | 10.3B | 8.9B | 7.8B | 6.8B | 5.1B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 13.3B | 11.0B | 9.9B | 8.9B | 7.1B |
Key Metrics | |||||
Total Debt | 2.0B | 2.0B | 2.7B | 3.8B | 1.1B |
Working Capital | 516.1M | 699.6M | 377.6M | 915.7M | 4.0B |
Balance Sheet Composition
Metropolis Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 1.9B | 1.7B | 1.9B | 2.9B | 2.4B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 70.1M | 14.2M | 2.9M | 68.6M | 77.9M |
Working Capital Changes | -228.7M | -17.0M | 125.9M | -32.2M | -391.8M |
Operating Cash Flow | 1.9B | 1.9B | 2.2B | 3.0B | 2.1B |
Investing Activities | |||||
Capital Expenditures | -414.1M | -637.6M | -524.8M | -306.6M | -281.9M |
Acquisitions | -1.3B | -6.5M | -4.5M | -6.4B | -53.9M |
Investment Purchases | -5.3B | -1.6B | -2.6B | -800.4M | 0 |
Investment Sales | 5.3B | 1.3B | 3.5B | 0 | 848.5M |
Investing Cash Flow | -1.8B | -915.8M | 398.4M | -7.6B | 458.8M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | -205.0M | -409.7M | -409.4M | -408.9M |
Debt Issuance | - | - | 0 | 6.0B | 0 |
Debt Repayment | -7.5M | -790.5M | -1.8B | -3.4B | -351.0K |
Financing Cash Flow | -7.4M | -995.4M | -2.2B | -1.2B | -74.7M |
Free Cash Flow | 1.9B | 2.0B | 1.9B | 2.2B | 2.2B |
Net Change in Cash | 118.9M | 25.6M | 416.6M | -5.7B | 2.5B |
Cash Flow Trend
Metropolis Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
69.22
Forward P/E
42.91
Price to Book
7.95
Price to Sales
7.96
PEG Ratio
5.17
Profitability Ratios
Profit Margin
10.89%
Operating Margin
10.14%
Return on Equity
11.96%
Return on Assets
7.15%
Financial Health
Current Ratio
1.18
Debt to Equity
15.30
Beta
0.09
Per Share Data
EPS (TTM)
₹29.52
Book Value per Share
₹256.94
Revenue per Share
₹259.73
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
metropolis | 106.0B | 69.22 | 7.95 | 11.96% | 10.89% | 15.30 |
Dr. Lal PathLabs | 268.6B | 52.27 | 12.35 | 22.08% | 20.29% | 7.14 |
Syngene | 262.6B | 51.97 | 5.56 | 10.50% | 13.61% | 12.23 |
Sai Life Sciences | 171.5B | 95.37 | 8.03 | 7.99% | 12.77% | 16.56 |
Vijaya Diagnostic | 107.1B | 71.11 | 13.43 | 17.90% | 21.04% | 39.99 |
Thyrocare | 70.9B | 66.67 | 12.96 | 16.73% | 14.69% | 4.51 |
Financial data is updated regularly. All figures are in the company's reporting currency.